Por: ABC News Health November 11, 2022
Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the Alzheimer’s treatment Aduhelm. The company said Thursday that the 62-year-old Viehbacher will become president and CEO on Monday, replacing Michel Vounatsos. Biogen said in May that Vounatsos would leave as soon as the company found a successor. The announcement came less than a year... + full article
Associated Press USA Health November 11, 2022
Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover from its failed launch of the . The company said Thursday that the 62-year-old Viehbacher will become president and CEO on Monday, replacing Michel... + más
Biogen tabs veteran pharma leader Viehbacher as next CEO | ABC News
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
Fox Business USA Business September 28, 2022
Dr. Stephen O'Brien, chief medical officer of Mediflix, shares how his streaming platform is trailblazing access to medical information for everyone. Shares of Biogen surged Wednesday's following news that its drug lecanemab showed promising signs of potentially... + más
Biogen shares rally as Alzheimer's drug results show promise | CBS News
Alzheimer's drug shows promise in early results of study | WPLG Local 10
The Boston Globe USA Business September 27, 2022
LIFE SCIENCESBiogen to pay $900m to settle whistle-blower suit over kickbacksAfter a decade of litigation, Biogen has agreed to pay $900 million to settle a federal whistle-blower lawsuit by a former employee who accused the Cambridge-based drug firm of paying kickbacks to... + más
Biogen pays $900m to settle whistle-blower suit over kickbacks | The Boston Globe
After a decade of litigation, Biogen has agreed to pay $900 million to settle a federal whistle-blower lawsuit by a former employee who accused the Cambridge-based drug firm of paying kickbacks to hundreds of doctors to get them to prescribe its multiple sclerosis drugs. Under... + más
Biogen to pay $900m to settle whistle-blower suit over kickbacks | The Boston Globe
Fox Business USA Business September 27, 2022
Aflac Chairman and CEO Dan Amos says record-high inflation poses a ‘challenging environment’ for consumers. Biogen has to settle allegations that it paid kickbacks to persuade doctors to prescribe its multiple sclerosis drugs. The settlement comes after former Biogen... + más
CNBC USA Health September 27, 2022
In this articleA Biogen facility in Cambridge, Massachusetts.Brian Snyder Reuters will pay $900 million to settle a lawsuit that alleged the company gave doctors kickbacks to encourage them prescribe its drugs, the Justice Department announced on Monday.A former Biogen employee... + más
About iurex | Privacy Policy | Disclaimer |